98%
921
2 minutes
20
Background: Right ventricular (RV) function is associated with a worse prognosis in patients with nonischemic cardiomyopathy (NICM), yet its evaluation may be challenging. Right atrial volume index (RAVI) and peak right atrial strain (PRAS) may reflect worse RV diastolic function, but their ability to identify patients at higher risk to predict clinical events among those with NICM has not been determined. The aim of this study was to investigate the value of right atrial strain analysis (RAVI and PRAS) in predicting cardiovascular mortality or heart failure hospitalization in a population of patients with NICM.
Methods: This was a retrospective, single-center, observational, longitudinal study. Patients with NICM with left ventricular ejection fractions <50% and without coronary disease were included, irrespective of atrial rhythm. The primary end point was major adverse cardiovascular events (MACE), a composite of heart failure hospitalization or cardiovascular death.
Results: Five hundred twelve patients were included. MACE occurred in 134 patients (26.2%) during a median follow-up period of 3.4 years. Multivariable analysis, including right atrial and RV echocardiographic parameters, identified an increase in RAVI (HR, 1.07 for a 5 mL/m increase; 95% CI, 1.01-1.13; P = .019) and a decrease in PRAS (HR, 0.84 per 5% increase; 95% CI, 0.71-0.99; P = .034) independently associated with MACE, with an additive value (increase in Harrell's C = 0.033, P = .043). RAVI remained associated with MACE after a Cox regression adjusted for age, hypertension, chronic kidney disease, and peak left atrial strain, with an HR of 1.05 for a 5 mL/m increase in RAVI (95% CI, 1.01-1.10; P = .025).
Conclusions: Among patients with NICM, a larger RAVI identifies those at higher risk for cardiovascular death or heart failure hospitalization. PRAS provides additive value to RAVI when assessing the risk for MACE in this population.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.echo.2025.06.012 | DOI Listing |
Cardiovasc Hematol Agents Med Chem
September 2025
Department of Hematology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China.
Background: Pulmonary Hypertension (PH) is a significant contributor to cardiac mortality in Dilated Cardiomyopathy (DCM) patients. Inflammatory processes and oxidative stress play pivotal roles in the advancement of Pulmonary Hypertension (PH). The Monocyte-to-High-- Density-Lipoprotein Cholesterol Ratio (MHR), a newly identified biomarker indicative of inflammatory and oxidative stress, has not been extensively researched in the context of pulmonary hypertension, especially within the scope of dilated cardiomyopathy.
View Article and Find Full Text PDFSurgeon
September 2025
Department of Vascular and Endovascular Surgery, Waterford University Hospital, Waterford, Ireland; University College Cork, Ireland; Department of Vascular and Endovascular Surgery, Faculty of Medicine, Mansoura University, Mansoura, Egypt. Electronic address:
Background: The management of diabetic foot infections (DFIs) is a complex multidisciplinary process and often necessitates surgical interventions. Unfortunately, amputations such as single or multiple toes amputations (MTA) or full transmetatarsal amputation (TMA) are often the unavoidable solution. This study aimed to compare the clinical outcomes of TMA versus MTA in managing non-ischemic diabetic foot infections.
View Article and Find Full Text PDFAm Heart J
September 2025
Baylor Scott and White Research Institute and HealthCare, Dallas TX. Electronic address:
Background: Current recommendations for a prophylactic (primary prevention) implantable cardioverter defibrillator (ICD) in patients with both ischemic and non-ischemic heart failure with reduced ejection fraction (HFrEF) originate from clinical trials conducted in selected patients over 20 years ago that showed an overall statistically significant survival benefit associated with a primary prevention ICD in the range of 23%-34%. The recent introduction of angiotensin receptor-neprilysin inhibitors [ARNI] and sodium glucose co-transporter 2 inhibitors [SGLT2i]) was shown to further reduce the risk of sudden cardiac death (SCD) in patients with HFrEF. Thus, there is an unmet need appropriately designed comparative effectiveness clinical trials aimed to reassess the survival benefit of a primary prevention ICD in contemporary patients with HFrEF.
View Article and Find Full Text PDFESC Heart Fail
September 2025
Department of Advanced Medical and Surgical Sciences (DAMSS), University of Campania 'Luigi Vanvitelli', Naples, Italy.
Aims: The current therapeutic approach to ischaemic (IsHF) and non-ischaemic (NIsHF) heart failure (HF) mainly overlooks the underlying aetiology owing to a lack knowledge of the differential molecular pathways that contribute to HF with reduced ejection fraction (HFrEF). Alterations in myocardial DNA methylation levels have been identified as potential biomarkers for HF irrespective of its aetiology. Due to the limited availability of cardiac tissues in clinics, our goal is to determine if DNA methylation changes in circulating CD4 T lymphocytes, which are strongly involved in left ventricle remodelling, can help in differentiating IsHF and NIsHF causes among patients with HFrEF and if DNA methylation levels associate with key clinical features.
View Article and Find Full Text PDFInt J Cardiovasc Imaging
September 2025
Heart & Vascular Institute, Henry Ford Hospital Detroit, Henry Ford West Bloomfield Hospital 5, West Bloomfield, MI, USA.
Transthoracic echocardiography (TTE) at the time of acute decompensated heart failure (ADHF) may reveal significant structural and hemodynamic abnormalities that can guide clinical management. However, the impact of routine repeat TTE in uncomplicated ADHF re-admissions is yet to be established. We studied patients with repeat TTE at the time of rehospitalization for ADHF to determine downstream clinical impact.
View Article and Find Full Text PDF